Across the entire spectrum of the life sciences sector, from academia and hospitals to pharmaceutical and biotech companies, enormous amounts of resources are invested in the development of new treatments to combat the largest public health challenges. This ranges from advanced cancer treatments that significantly improve survival, to treating previously untreatable diseases through gene therapy. The absolute breakthrough in nanomedicine technology was recently signified with over 70% of the global population having now received a COVID-19 vaccination, many of which were mRNA vaccines. However, the technologies available to analyse these new medicines continue to lag behind. There remains a largely unmet need for specifically designed analytical tools that are more sensitive and capable of accelerating R&D and improving quality control of nanoformulations. This presentation will guide you through a range of novel analytical approaches, their capabilities, goals and limitations to improve translation and efficacy of these novel therapies.

Learning Objectives:

• Review what kinds of nanoformulations and non-viral modalities are available and in development and their key characteristics
• Discuss the key analytical challenges in the development and translation of these new modalities
• Describe the core concepts of novel analytical techniques addressing these analytical challenges